Lantheus Holdings, Inc.

Good morning. Welcome to the Lantheus fourth quarter and full year 2024 conference call. All lines have been placed on mute. This call is being recorded and a replay will be available in the investor section of the company's website approximately two hours after the completion of the call. The call will be archived for at least 30 days. I'll now turn the call over to Mark Canarni, Vice President of Investor Relations. Mark?

Thank you. Good morning. With me today are Brian Markison, our CEO, Paul Blanchfield, our President, Bob Marshall, our CFO, and Amanda Morgan, our Chief Commercial Officer. We will begin with prepared remarks and then open the call for Q&A. This morning we issued a press release which was furnished to the SEC under Form 8K reporting our fourth quarter 2024 results. The release and today's slide presentation are in the investor section of our website. Any comments made could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties which are detailed in our SEC filings. Discussions will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the investor section of our website. I will now turn the call over to our CEO, Brian.

Thank you, Mark, and good morning, everyone. 2024 was a groundbreaking year for Lantheus as we achieved a number of important milestones and enhanced our capabilities as the leading radiopharmaceutical focus company. I am immensely proud of our team and the meaningful difference we have made in the lives of over 7 million patients in 2024. Our strong performance in the fourth quarter and throughout all of 2024 was driven by our commitment to operational excellence, we remain focused on further expanding our radiopharmaceutical excellence through a leading commercial portfolio, innovative pipeline, and differentiated capabilities. Last month, we announced two strategic transactions that have the potential to, first, enhance our capabilities across the radiopharmaceutical value chain, including in Alzheimer's diagnostics and oncology therapeutics. Second, Allow us to enter new markets with significant growth potential that diversify our business. Third, expand our pipeline with potentially best or first in class radiopharmaceutical theranostic pairs that make use of our existing expertise. And fourth, help to drive sustained double digit revenue growth beginning in 2026. Life molecular imaging will support our future growth with the addition of NeuroSeq, an approved radio diagnostic for Alzheimer's disease, expand our capabilities with an Alzheimer's commercial franchise, as well as an enhanced R&D and clinical development capabilities, and grow our pipeline. Evergreen Theragnostics has the potential to add Octevi, a registrational stage pet radio diagnostic that complements our therapeutic registrational stage candidate, PNT, strengthen our clinical and commercial manufacturing capabilities, add multiple clinical and preclinical assets to the pipeline, and enhance our early stage R&D capabilities quite significantly. Both acquisitions are subject to customary closing conditions and are expected to close in the second half of this year. Throughout 2024, we also executed a series of asset and licensing deals to expand our pipeline. We are excited about these potentially best or first in class agents for Alzheimer's disease and oncology and plan to advance them during the year. Operationally, we grew Polarify to over $1 billion in sales, making it the first ever radio diagnostic blockbuster and the clear number one utilized PSMA PET imaging agent. We also grew our market leading ultrasound enhancing agent, Affinity, double digits in its 24th year on the market. In November, CMS issued its calendar year 2025 rule, which enhanced payment for specialized diagnostic radiopharmaceuticals for covered products. This was a significant step that will support long-term radiopharmaceutical diagnostic innovation. We enter 2025 focused on leading the Renaissance in radiopharmaceuticals, growing both our flagship diagnostic agents advancing our pipeline, closing our two recently announced transactions, and delivering value to our patients, customers, employees, and shareholders. With that, I'll turn the call over to Paul to provide an update on our operational performance.